Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks 'World Health Day' 2025 in partnership with Africa's First Ladies who ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay. In a push to keep the Keytruda gravy train on the ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...